Skip to main content

Enzyme offers new therapeutic target for...

Enzyme offers new therapeutic target for cancer drugs

New cancer drugResearchers at the University of California, San Diego School of Medicine have uncovered a new signal transduction pathway specifically devoted to the regulation of alternative RNA splicing, a process that allows a single gene to produce or code multiple types of protein variants. The discovery, published in the June 27, 2012 issue of Molecular Cell, suggests the new pathway might be a fruitful target for new cancer drugs.

Signal transduction in the cell involves kinases and phosphatases, enzymes that transfer or remove phosphates in protein molecules in a cascade or pathway. SRPK kinases, first described by Xiang-Dong Fu, PhD, professor of cellular and molecular medicine at UC San Diego in 1994, are involved in controlling the activities of splicing regulators in mammalian cells.

Prior studies have implicated SRPK1 in cancer and other human diseases. For example, it has been shown that SRPK1 plays a critical role in regulating the function of Vascular Endothelial Growth Factor or VEGF, which stimulates blood vessel growth in cancer. SRPK1 has been found to be dysregulated in a number of cancers, from kidney and breast to lung and pancreatic.

Daily cup of coffee could help fight can...

Daily cup of coffee could help fight cancer

Coffee may help fight cancer
SEATTLE — Caffeine may do more than just help you wake up each morning. According to a study published Monday in the Proceedings of the National Academy of Sciences, it can also guard against certain skin cancers.

Researchers at both the University of Washington and Rutgers University say caffeine inhibits a DNA repair pathway, helping kill cells damaged by the sun.

Experts suggest that moderate caffeine drinking, or caffeine based lotion, could be useful in preventing skin cancer.